Company: SHPH
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001493152-25-008474
Chunk: 123

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-27
Form: 424B3
Chunk 123
---
 Accelerated Feature |          — |   |
|:------------------------------------------------------------------------|:----|:---------|----------:|:--|:----|:-------------------------|-----------:|:--|
| Addition of new derivative                                              |     |          | 1,189,000 |   |     |                          |  1,442,000 |   |
| Gain on change in fair value                                            |     |          |  (778,340 | ) |     |                          | (1,438,148 | ) |
| Balance - December 31, 2023                                             |     |          |   410,660 |   |     |                          |      3,852 |   |
| Addition of new derivatives                                             |     |          |   166,558 |   |     |                          |          — |   |
| Gain on change in fair value                                            |     |          |  (551,937 | ) |     |                          |     (3,852 | ) |
| Balance - December 31, 2024                                             |     | $        |    25,281 |   |     | $                        |          — |   |

Note 8 – Commitments and Contingencies

On December 16, 2024, the Company entered into a sponsored research agreement (the “Sponsored Research Agreement”) with the Regents of the University of California, on behalf of its San Francisco campus (the “UCSF”), pursuant to which UCSF’s employee will conduct research on a project entitled “Investigation of 18F-fluorodeboronation method for PSMA targeting ligand radiolabeling and evaluation in prostate cancer models” (the “Research Program”). Under the terms of the Sponsored Research Agreement, the Company will bear the total cost of $0.3 million of the Research Program and has an exclusive license to the intellectual property underlying the research. This Sponsored Research Agreement will be effective for a period of one year and may be extended by written mutual consent of the parties. During the year ended December 31, 2024, the Company made no payments nor incurred any costs under the Sponsored Research Agreement.

Note 9 – Business Segment Information

The Company operates as one operating segment with a focus on products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of radiation therapy. The CEO, as our chief operating decision maker (CODM), manages and allocates resources to the operations of the Company on a consolidated basis, considering